Skip to main content
. Author manuscript; available in PMC: 2011 Mar 5.
Published in final edited form as: J Mol Biol. 2010 Jan 11;396(4):858–869. doi: 10.1016/j.jmb.2010.01.014

Figure 1.

Figure 1

Overexpression of TRPM7 in HEK-293 cells activates p38 MAPK and JNK, but suppresses ERK. (a) Application of the p38 MAPK inhibitor SB203580 (1 μM) and JNK inhibitor SP600125 (20 μM) to 293-TRPM7 cells treated with tetracycline (+TET) for 24 hours reduced TRPM7-induced cell rounding to levels similar to cells grown in the absence of tetracycline. In contrast, treatment of cells with the MEK1/2 inhibitors U0126 (5 μM) and PD98059 (10 μM) had only a partial effect. Scale bar is equal to 100 μm. (b) Quantification of the degree of cell rounding under the conditions depicted in (a). Values are mean ± standard deviation of at least three independent experiments. A χ2 test was employed to assess differences in cell rounding between 293-TRPM7 cells treated with the different inhibitors. An asterisk indicates treatments that produced a decrease in cell rounding that was significantly different from 293-TRPM7 cells grown in tetracycline. (c) Western blots showing expression of TRPM7 or kinase-inactive TRPM7-G1618D mutant (+TET) caused a modest increase in p38 MAPK and JNK activities and a reduction in ERK activation. “NT” is non-transfected HEK-293 cells.